Trial Profile
Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 07 Jun 2022 Planned End Date changed from 1 May 2023 to 1 Jun 2027.
- 07 Jun 2022 Planned primary completion date changed from 1 May 2022 to 1 Jun 2027.
- 05 Oct 2021 Planned End Date changed from 1 May 2022 to 1 May 2023.